Clinical Outcome of Intra Articular Injection of Autologous Platelet Rich Plasma in Anterior Cruciate Ligament Injury.

Clinical Outcome of Intra Articular Injection of Autologous Platelet Rich Plasma in Anterior Cruciate Ligament Injury.

This clinical trial will evaluate the effectiveness of platelet-rich plasma (PRP) injections for patients with anterior cruciate ligament (ACL) injury. ACL injuries commonly cause knee instability, pain, and reduced function, and rehabilitation alone may not fully restore recovery in all patients. PRP is prepared from a small sample of the patient's own blood and contains natural growth factors that may promote healing and improve joint function.

In this study, participants will be randomly assigned to one of two groups. The experimental group will receive a single ultrasound-guided injection of PRP into the knee joint along with a standard rehabilitation program. The control group will receive the rehabilitation program alone.

Participants will be followed up at 3 weeks, 8 weeks, and 16 weeks after treatment. At each follow-up visit, knee function, pain level, and physical performance will be assessed using validated outcome measures. The primary aim is to determine whether PRP provides additional benefit compared with rehabilitation alone in improving function and reducing symptoms in ACL-injured patients.

This study will provide new evidence about the role of PRP in ACL management, which may help guide future treatment decisions.

Inclusion criteria:

• Patients of both sexes who are older than 18 years and younger than 50 years
• 3 or Less than 3-months history of knee injuries
• ACL injury MRI Grade 1 (Low) and medium Grade 2 (Medium) grade
• ACL injury associated with Grade 1 or 2 Posterior cruciate ligament (PCL) tear and/or Grade 1 or 2 meniscal tear
• The Complete Blood Count (CBC) report shows a hemoglobin > 10gm/dl and platelet count >150,000/microliter prior to the procedure
• Capable of comprehending informed consent

Exclusion criteria:

• Patients who have had intra articular corticosteroid injections in the index knee during the last 12 weeks
• Patients who are taking systemic steroid
• Patients who are younger than 18 and older than 50 years
• Those with a history of platelet disorders or on the therapeutic anticoagulant or anti platelet drugs
• Hemoglobin below 10 gm/dl
• Platelet count <150000/microliter
• Complete tear of both bundles on MRI
• Grade 3 or more PCL and meniscal tear on MRI
• Previous or concurrent ligament reconstruction in the index knee joint.
• Connective tissue disorders like Marfan Syndrome, Ehler-Danlos Syndrome etc.
• Any inflammatory disease like Rheumatoid Arthritis, spondyloarthritis, gout, pseudogout etc involving the knee joint.